ArticleJournal of thoracic disease2024
Treating deep sternal wound infection with pectoralis major flap transposition: a systemic factor analysis of efficacy and safety.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deep sternal wound infection (DSWI) is a life-threatening postoperative complication of cardiac surgery. Currently, there are many therapies used to treat patients with DSWI. However, none of these therapies have been shown to be the optimal choice for patients with DSWI. Additionally, these methods may require additional facilities which limit their widespread use. Therefore, we aimed to investigate the effectiveness, safety, and risk factors related to the prognosis of DSWI patients treated with pectoralis major flap transposition (PMFT), a more concise method. Methods: A retrospective, systemic analysis was conducted of DSWI patients at the Beijing Anzhen Hospital from January 2010 until December 2020. All the patients were diagnosed with DSWI according to the relevant guidelines, and treated with PMFT. The patients were divided into the following two groups based on their prognosis after treatment with PMFT: (I) the wound healing (WH) group; and (II) the delayed wound healing or death (DWHD) group. All the participants were followed up for 1 year. Results: In total, 9.7% (76/785) of the DSWI patients experienced DWHD in the present study. The all-cause mortality rate was 3.7% (29/785). While 90.3% (709/785) of the patients achieved WH after undergoing PMFT. The multivariate logistic regression model indicated that patients with diabetes mellitus, obesity, a history of smoking, abnormal liver function, anemia, chronic infection, immune disease, hypothermia, a longer gap time, and patients requiring extracorporeal membrane oxygenation (ECMO) assistance, salvage surgery, and secondary cardiac surgery were more likely to experience DWDH. Conclusions: This study showed PMFT was a safe and effective method for treating DSWI after cardiac surgery. Patients with risk factors, such as those mentioned above, require more attention. Prospective studies should be conducted to explore the relationships among the novel risk factors and DSWI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.